{"id":"https://openalex.org/W2276971282","doi":"https://doi.org/10.1200/jco.2011.29.15_suppl.3102","title":"First-in-human trial of a poly(ADP)-ribose polymerase (PARP) inhibitor MK-4827 in advanced cancer patients with antitumor activity in BRCA-deficient tumors and sporadic ovarian cancers (soc).","display_name":"First-in-human trial of a poly(ADP)-ribose polymerase (PARP) inhibitor MK-4827 in advanced cancer patients with antitumor activity in BRCA-deficient tumors and sporadic ovarian cancers (soc).","publication_year":2011,"publication_date":"2011-05-20","ids":{"openalex":"https://openalex.org/W2276971282","doi":"https://doi.org/10.1200/jco.2011.29.15_suppl.3102","mag":"2276971282"},"language":"en","primary_location":{"id":"doi:10.1200/jco.2011.29.15_suppl.3102","doi":"https://doi.org/10.1200/jco.2011.29.15_suppl.3102","is_oa":false,"landing_page_url":"https://doi.org/10.1200/jco.2011.29.15_suppl.3102","pdf_url":null,"source":{"id":"https://openalex.org/S15137598","display_name":"Journal of Clinical Oncology","issn_l":"0732-183X","issn":["0732-183X","1527-7755"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310315671","host_organization_name":"Lippincott Williams & Wilkins","host_organization_lineage":["https://openalex.org/P4310315671","https://openalex.org/P4310318547"],"host_organization_lineage_names":["Lippincott Williams & Wilkins","Wolters Kluwer"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Journal of Clinical Oncology","raw_type":"journal-article"},"volume":null,"type":"conference-abstract","indexed_in":["crossref"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5073864381","display_name":"William R. Schelman","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"W. R. Schelman","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5064026461","display_name":"Shahneen Kaur Sandhu","orcid":"https://orcid.org/0000-0002-8660-4475","observed_orcids":["https://orcid.org/0000-0002-8660-4475"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"S. K. Sandhu","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":null,"display_name":"V. Moreno Garcia","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"V. Moreno Garcia","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5061697254","display_name":"George Wilding","orcid":"https://orcid.org/0009-0000-5775-5293","observed_orcids":["https://orcid.org/0009-0000-5775-5293"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"G. Wilding","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5012278970","display_name":"Long Sun","orcid":"https://orcid.org/0000-0002-3869-4832","observed_orcids":["https://orcid.org/0000-0002-3869-4832","https://orcid.org/0000-0002-0318-2925"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"L. Sun","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5015441971","display_name":"Carlo Toniatti","orcid":"https://orcid.org/0000-0001-9493-344X","observed_orcids":["https://orcid.org/0000-0001-9493-344X"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"C. Toniatti","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5062831066","display_name":"Mark Stroh","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"M. Stroh","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5036932100","display_name":"N. Kreischer","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"N. Kreischer","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":null,"display_name":"C. L. Carpenter","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"C. L. Carpenter","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5013897432","display_name":"L. Rhoda Molife","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"L. R. Molife","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5014804968","display_name":"Stan B. Kaye","orcid":"https://orcid.org/0000-0003-3318-8575","observed_orcids":["https://orcid.org/0000-0003-3318-8575"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"S. B. Kaye","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5072378199","display_name":"Johann Sebastian De Bono","orcid":"https://orcid.org/0000-0002-2034-595X","observed_orcids":["https://orcid.org/0000-0002-2034-595X"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"J. S. De Bono","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"last","author":{"id":"https://openalex.org/A5027002350","display_name":"Robert M. Wenham","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"R. M. Wenham","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]}],"institutions":[],"countries_distinct_count":0,"institutions_distinct_count":0,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":null,"apc_paid":null,"fwci":null,"has_fulltext":false,"cited_by_count":57,"citation_normalized_percentile":null,"cited_by_percentile_year":null,"biblio":{"volume":"29","issue":"15_suppl","first_page":"3102","last_page":"3102"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T11914","display_name":"PARP inhibition in cancer therapy","score":1.0,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T11914","display_name":"PARP inhibition in cancer therapy","score":1.0,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10769","display_name":"BRCA gene mutations in cancer","score":0.0,"subfield":{"id":"https://openalex.org/subfields/1311","display_name":"Genetics"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T12829","display_name":"Advanced Breast Cancer Therapies","score":0.0,"subfield":{"id":"https://openalex.org/subfields/2740","display_name":"Pulmonary and Respiratory Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/parp-inhibitors","display_name":"PARP inhibitors","score":0.8209999799728394},{"id":"https://openalex.org/keywords/parp1-2-inhibition","display_name":"PARP1/2 inhibition","score":0.7870000004768372},{"id":"https://openalex.org/keywords/brca-mutation-carriers","display_name":"BRCA mutation carriers","score":0.765999972820282},{"id":"https://openalex.org/keywords/homologous-recombination-deficiency","display_name":"homologous recombination deficiency","score":0.8690000176429749},{"id":"https://openalex.org/keywords/synthetic-lethality","display_name":"synthetic lethality","score":0.9779999852180481},{"id":"https://openalex.org/keywords/sporadic-ovarian-cancer","display_name":"sporadic ovarian cancer","score":0.949999988079071},{"id":"https://openalex.org/keywords/sporadic-breast-cancer","display_name":"sporadic breast cancer","score":0.7730000019073486},{"id":"https://openalex.org/keywords/advanced-solid-tumors","display_name":"advanced solid tumors","score":0.5889999866485596},{"id":"https://openalex.org/keywords/maximum-tolerated-dose","display_name":"maximum tolerated dose","score":0.7390000224113464},{"id":"https://openalex.org/keywords/dose-limiting-toxicity","display_name":"dose-limiting toxicity","score":0.9139999747276306},{"id":"https://openalex.org/keywords/pharmacokinetics","display_name":"pharmacokinetics","score":0.8970000147819519},{"id":"https://openalex.org/keywords/pharmacodynamics","display_name":"pharmacodynamics","score":0.9070000052452087}],"concepts":[{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.8411667346954346},{"id":"https://openalex.org/C2779138821","wikidata":"https://www.wikidata.org/wiki/Q7118227","display_name":"PARP inhibitor","level":5,"score":0.6360754370689392},{"id":"https://openalex.org/C2778375690","wikidata":"https://www.wikidata.org/wiki/Q7814214","display_name":"Tolerability","level":3,"score":0.6319882869720459},{"id":"https://openalex.org/C197934379","wikidata":"https://www.wikidata.org/wiki/Q2047938","display_name":"Adverse effect","level":2,"score":0.5708234310150146},{"id":"https://openalex.org/C111113717","wikidata":"https://www.wikidata.org/wiki/Q725307","display_name":"Pharmacodynamics","level":3,"score":0.5360133647918701},{"id":"https://openalex.org/C2780580376","wikidata":"https://www.wikidata.org/wiki/Q186889","display_name":"Nausea","level":2,"score":0.506369948387146},{"id":"https://openalex.org/C121608353","wikidata":"https://www.wikidata.org/wiki/Q12078","display_name":"Cancer","level":2,"score":0.49548304080963135},{"id":"https://openalex.org/C29730261","wikidata":"https://www.wikidata.org/wiki/Q274160","display_name":"Toxicity","level":2,"score":0.49327462911605835},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.48803773522377014},{"id":"https://openalex.org/C137061746","wikidata":"https://www.wikidata.org/wiki/Q736033","display_name":"Peripheral blood mononuclear cell","level":3,"score":0.4756723940372467},{"id":"https://openalex.org/C98274493","wikidata":"https://www.wikidata.org/wiki/Q128406","display_name":"Pharmacology","level":1,"score":0.46341270208358765},{"id":"https://openalex.org/C2781312401","wikidata":"https://www.wikidata.org/wiki/Q7919041","display_name":"Veliparib","level":5,"score":0.4415457844734192},{"id":"https://openalex.org/C112705442","wikidata":"https://www.wikidata.org/wiki/Q323936","display_name":"Pharmacokinetics","level":2,"score":0.4311046600341797},{"id":"https://openalex.org/C182979987","wikidata":"https://www.wikidata.org/wiki/Q3907241","display_name":"Poly ADP ribose polymerase","level":4,"score":0.37305086851119995},{"id":"https://openalex.org/C143998085","wikidata":"https://www.wikidata.org/wiki/Q162555","display_name":"Oncology","level":1,"score":0.3498871326446533},{"id":"https://openalex.org/C82381507","wikidata":"https://www.wikidata.org/wiki/Q416878","display_name":"Polymerase","level":3,"score":0.14428776502609253},{"id":"https://openalex.org/C202751555","wikidata":"https://www.wikidata.org/wiki/Q221681","display_name":"In vitro","level":2,"score":0.09855756163597107},{"id":"https://openalex.org/C86803240","wikidata":"https://www.wikidata.org/wiki/Q420","display_name":"Biology","level":0,"score":0.08899664878845215},{"id":"https://openalex.org/C55493867","wikidata":"https://www.wikidata.org/wiki/Q7094","display_name":"Biochemistry","level":1,"score":0.0},{"id":"https://openalex.org/C104317684","wikidata":"https://www.wikidata.org/wiki/Q7187","display_name":"Gene","level":2,"score":0.0}],"mesh":[],"locations_count":1,"locations":[{"id":"doi:10.1200/jco.2011.29.15_suppl.3102","doi":"https://doi.org/10.1200/jco.2011.29.15_suppl.3102","is_oa":false,"landing_page_url":"https://doi.org/10.1200/jco.2011.29.15_suppl.3102","pdf_url":null,"source":{"id":"https://openalex.org/S15137598","display_name":"Journal of Clinical Oncology","issn_l":"0732-183X","issn":["0732-183X","1527-7755"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310315671","host_organization_name":"Lippincott Williams & Wilkins","host_organization_lineage":["https://openalex.org/P4310315671","https://openalex.org/P4310318547"],"host_organization_lineage_names":["Lippincott Williams & Wilkins","Wolters Kluwer"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Journal of Clinical Oncology","raw_type":"journal-article"}],"best_oa_location":null,"sustainable_development_goals":[{"score":1.0,"id":"https://metadata.un.org/sdg/3","display_name":"Good health and well-being"}],"study_designs":[],"awards":[],"funders":[],"has_content":{"pdf":false,"grobid_xml":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W4249199995","https://openalex.org/W2171474267","https://openalex.org/W15193367","https://openalex.org/W2128746885","https://openalex.org/W2599038431","https://openalex.org/W2160399783","https://openalex.org/W2061827661","https://openalex.org/W2171972386","https://openalex.org/W2033108966","https://openalex.org/W3093265161"],"abstract_inverted_index":{"3102":[0],"Background:":[1],"MK4827":[2,85,195],"is":[3,332],"an":[4],"orally":[5],"active,":[6],"PARP":[7,225],"1/2":[8],"inhibitor":[9],"with":[10,25,33,66,140,212,253,269,274],"nanomolar":[11],"potency.":[12],"It":[13],"induces":[14],"selective":[15],"synthetic":[16],"lethality":[17],"in":[18,29,86,131,162,168,175,183,227,241,315,324],"homologous":[19],"recombination":[20],"(HR)":[21],"repair":[22],"deficient":[23],"tumors":[24,69,327],"BRCA1/2":[26],"loss":[27],"and":[28,51,55,59,75,98,155,179,205,244,272,294,311,318,336],"tumor":[30],"cell":[31],"lines":[32],"non-BRCA-related":[34],"HR":[35,77,330],"defects,":[36],"supporting":[37],"broad":[38],"clinical":[39],"application.":[40],"A":[41],"phase":[42],"I":[43],"study":[44],"was":[45,93,160,190,210,239,301],"undertaken":[46],"to":[47,120],"determine":[48],"the":[49,145],"toxicity":[50],"tolerability,":[52],"pharmacokinetic":[53],"(PK)":[54],"pharmacodynamic":[56],"(PD)":[57],"profiles,":[58],"preliminary":[60],"anti-tumor":[61],"activity.":[62],"Methods:":[63],"Patients":[64],"(p)":[65],"advanced":[67],"solid":[68],"enriched":[70,328],"for":[71,329],"BRCA-mutation":[72],"carriers":[73],"(BRCA-MC)":[74],"non-BRCA":[76],"defects":[78,331],"received":[79],"once":[80],"daily,":[81],"escalating":[82],"doses":[83,233],"of":[84,88,125,216,234,308],"cohorts":[87],"3-6":[89],"p.":[90],"Dose":[91,207],"escalation":[92],"guided":[94],"by":[95,134],"toxicity,":[96],"PK":[97,209],"PD":[99,222],"data.":[100],"Results:":[101],"60":[102],"p":[103,139],"(M13,":[104],"F47;":[105],"median":[106],"age":[107],"56":[108],"yr;":[109],"21":[110],"BRCA-MC)":[111,285],"were":[112,142,150],"treated":[113,185],"at":[114,144,170,177,186,192,232],"10":[115],"dose":[116],"levels":[117],"from":[118,291,296],"30mg":[119],"400mg":[121],"on":[122],"days":[123,293],"1-21":[124],"a":[126,213],"28":[127],"day":[128],"cycle":[129],"(C)":[130],"C1,":[132],"followed":[133],"continuous":[135],"dosing.":[136],"20":[137],"additional":[138],"soc":[141],"enrolled":[143],"MTD.":[146],"Prior":[147],"systemic":[148],"treatments":[149],"\u22642":[151],"(23p),":[152],"\u22653":[153],"(17p),":[154],"\u22654":[156],"(40p).":[157],"Overall,":[158],"DLT":[159],"observed":[161,211,240],"4p:":[163],"grade":[164],"(G)":[165],"3":[166,261],"fatigue":[167],"1/6p":[169,176],"30mg,":[171],"reversible":[172,180,198],"G3":[173],"pneumonitis":[174],"60mg,":[178],"G4":[181],"thrombocytopenia":[182],"2/6p":[184],"400mg.":[187],"The":[188],"MTD":[189],"established":[191],"300mg.":[193],"Other":[194],"related":[196],"G1-2":[197],"adverse":[199],"events":[200],"included":[201],"fatigue,":[202],"anorexia,":[203],"nausea":[204],"myelosuppression.":[206],"proportional":[208],"mean":[214],"t1/2":[215],"40":[217],"hours":[218],"(range":[219],"37-42":[220],"hr).":[221],"studies":[223],"confirmed":[224],"inhibition":[226],"peripheral":[228],"blood":[229],"mononuclear":[230],"cells":[231],"\u226580":[235],"mg.":[236],"Antitumor":[237],"activity":[238,314],"both":[242,316],"sporadic":[243,319],"BRCA-MC":[245,266,317],"cancers.":[246],"In":[247],"total,":[248],"there":[249],"have":[250,289],"been":[251],"12p":[252],"partial":[254],"responses":[255],"(PR)":[256],"(10":[257],"ovarian":[258,279],"[7":[259],"BRCA-MC;":[260],"soc],":[262],"2":[263,282],"breast,":[264],"10/12":[265],"cancers,":[267],"4/12":[268],"ongoing":[270],"treatment),":[271],"8p":[273],"stable":[275],"disease":[276],"(SD)":[277],"(4":[278],"[2":[280],"BRMC-MC],":[281],"NSCLC,":[283],"2/4":[284],"\u2265120":[286],"days.":[287,298],"PRs":[288],"ranged":[290],"86(+)-483":[292],"SD":[295],"18(+)-354":[297],"Conclusions:":[299],"MK-4827":[300],"well":[302],"tolerated,":[303],"had":[304],"linear":[305],"PKs,":[306],"evidence":[307],"target":[309],"modulation,":[310],"promising":[312],"antitumor":[313],"cancer.":[320],"Specific":[321],"cohort":[322],"expansions":[323],"other":[325],"nonhereditary":[326],"ongoing.":[333],"Updated":[334],"safety":[335],"response":[337],"data":[338],"will":[339],"be":[340],"provided.":[341]},"counts_by_year":[{"year":2021,"cited_by_count":1},{"year":2020,"cited_by_count":1},{"year":2017,"cited_by_count":1},{"year":2016,"cited_by_count":4},{"year":2015,"cited_by_count":1},{"year":2014,"cited_by_count":7},{"year":2013,"cited_by_count":7},{"year":2012,"cited_by_count":9}],"updated_date":"2026-10-16T09:59:22.235173","created_date":"2016-06-24T00:00:00"}